Novartis plans to expand its US-based manufacturing and R&D footprint with a total investment of $23B over the next 5 years

Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities With new manufacturing capacity, Novartis will be able to produce 100% of its key medicines end-to-end in the US, a significant increase from current levels Increased R&D presence…